What Oregon’s Measure 109 Means for Hopeful Entrepreneurs and Investors Feb 9 • 6 min read While entrepreneurs and investors are likely to see Oregon’s Measure 109 as a chance to capitalize on new business opportunities and investments, it’s worth highlighting that this new law is unlikely to lead to a psilocybin gold rush.
Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller Feb 9 • 3 min read Tryp Therapeutics announced it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms associated with eating disorders.
Bright Minds Biosciences Announces Listing on Canadian Stock Exchange Feb 8 • 2 min read Bright Minds Biosciences today announced that the company’s common shares are expected to commence trading on the Canadian Securities Exchange on Monday, February 8, 2021, under the ticker symbol “DRUG.”
Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds Feb 5 • 3 min read Mindset Pharma Inc. announced that the company has filed 3 final patent applications with the U.S. Patent and Trademark Office.
Dr. Robin Carhart-Harris joins Osmind as a Scientific Advisor Feb 4 • 3 min read Osmind is adding Dr. Robin Carhart-Harris as a Scientific Advisor.